Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ShareHope Medicine Co., Ltd. (8403.TWO)
Taoyuan City, TW
ShareHope Medicine Co., Ltd., a company based in Taiwan, delivers a wide array of integrated healthcare solutions. Its operations encompass health management and administrative services, the provision of skilled medical professionals for staffing needs, and the distribution of various medical, pharmaceutical, and general health-related devices. The company also offers remote healthcare, often referred to as telemedicine, and facilitates the rental of essential medical equipment. ShareHope Medicine Co., Ltd. was established in 2003 and operates from its headquarters in Taoyuan City, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.49% | -4.71% | -8.99% | -14.56% | -16.32% | -13.28% | -25.52% | -37.83% | -19.90% | -20.46% | +125.75% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+0.7% Q1'26: +2.4% (vs Q1'25)
-
EPS growth Medical - Care Facilities: +19.2%-32.2% Q1'26: -45.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+2.4% Q1'26: +6.9% (vs Q1'25)
-
EBIT margin Medical - Care Facilities: +11.3%+3.9% Q1'26: +1.6% (vs Q1'25)
-
ROIC Medical - Care Facilities: +6.8%+3.1% Q1'26: +1.0% (vs Q1'25)
-
Share dilution Medical - Care Facilities: +0.0%-17.5% ★ Q1'26: -41.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×10.53× Q1'26: 25.70× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.14B
est.
|
2.30B
est.
|
2.30B
est.
|
2.62B
est.
|
3.12B
est: 2.97B (+5.0%)
|
4.10B
est: 4.02B (+2.0%)
|
3.85B
est: 3.67B (+4.9%)
|
4.33B
est: 2.30B (+88.4%)
|
4.36B
est: 2.30B (+89.8%)
|
2.62B
2.62B – 2.62B
+14.3% YoY
|
2.97B
2.97B – 2.97B
+13.3% YoY
|
4.02B
4.02B – 4.02B
+35.2% YoY
|
3.67B
3.67B – 3.67B
-8.7% YoY
|
| EBITDA |
317.41M
est.
|
341.33M
est.
|
341.33M
est.
|
390.09M
est.
|
271.51M
est: 442.12M (-38.6%)
|
712.22M
est: 597.62M (+19.2%)
|
592.51M
est: 545.59M (+8.6%)
|
539.82M
est: 279.54M (+93.1%)
|
170.86M
est: 279.54M (-38.9%)
|
319.48M
319.48M – 319.48M
+14.3% YoY
|
362.09M
362.09M – 362.09M
+13.3% YoY
|
489.44M
489.44M – 489.44M
+35.2% YoY
|
446.83M
446.83M – 446.83M
-8.7% YoY
|
| EBIT |
163.69M
est.
|
176.02M
est.
|
176.02M
est.
|
201.17M
est.
|
138.99M
est: 228.00M (-39.0%)
|
493.62M
est: 308.19M (+60.2%)
|
287.76M
est: 281.36M (+2.3%)
|
232.25M
est: 138.47M (+67.7%)
|
170.86M
est: 138.47M (+23.4%)
|
158.26M
158.26M – 158.26M
+14.3% YoY
|
179.37M
179.37M – 179.37M
+13.3% YoY
|
242.45M
242.45M – 242.45M
+35.2% YoY
|
221.34M
221.34M – 221.34M
-8.7% YoY
|
| Net Income |
344.96M
est.
|
175.91M
est.
|
175.91M
est.
|
159.64M
est.
|
195.05M
est: 156.89M (+24.3%)
|
247.71M
est: 309.47M (-20.0%)
|
232.66M
est: 190.26M (+22.3%)
|
200.10M
est: 145.17M (+37.8%)
|
111.90M
est: 138.25M (-19.1%)
|
125.47M
125.47M – 125.47M
-9.2% YoY
|
123.31M
123.31M – 123.31M
-1.7% YoY
|
243.23M
243.23M – 243.23M
+97.3% YoY
|
149.53M
149.53M – 149.53M
-38.5% YoY
|
| SGA |
370.13M
est.
|
398.01M
est.
|
398.01M
est.
|
454.87M
est.
|
546.41M
est: 515.55M (+6.0%)
|
706.89M
est: 696.87M (+1.4%)
|
664.41M
est: 636.20M (+4.4%)
|
727.54M
est: 318.82M (+128.2%)
|
—
est: 318.82M (-100.0%)
|
364.37M
364.37M – 364.37M
+14.3% YoY
|
412.97M
412.97M – 412.97M
+13.3% YoY
|
558.22M
558.22M – 558.22M
+35.2% YoY
|
509.61M
509.61M – 509.61M
-8.7% YoY
|
| EPS |
2.62
est.
|
1.34
est.
|
1.34
est.
|
1.21
est.
|
1.46
est: 1.19 (+22.5%)
|
1.98
est: 2.35 (-15.8%)
|
1.85
est: 1.45 (+28.0%)
|
1.53
est: 1.34 (+14.5%)
|
1.03
est: 1.27 (-19.1%)
|
1.15
1.15 – 1.15
-9.2% YoY
|
1.14
1.14 – 1.14
-1.7% YoY
|
2.24
2.24 – 2.24
+97.3% YoY
|
1.38
1.38 – 1.38
-38.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-08 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-07 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-06 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-05 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-04 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-30 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-29 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-22 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-21 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-20 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-17 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-16 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis Emerging Markets Value ETF AVES | 0.00% | 12.4K | 0.36% |
| 2 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 54.3K | 0.39% |
| 3 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 83.1K | 0.33% |
| 4 | Avantis Responsible Emerging Markets Equity ETF AVSE | 0.00% | 687.68 | 0.33% |
| 5 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 34.0K | 0.28% |
| 6 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 22.2K | 0.29% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ching-Wen Liu | GM & Director | — | male |
| Ya-Mei Huang | Accounting Supervisor | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 8403.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
